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Abstract
Measures of immune outcomes in youth who initiate combination antiretroviral therapy (cART)
early in HIV infection are limited.
Design—Adolescent Trials Network 061 examined changes over 48 weeks of cART in T cell
subsets and markers of T cell and macrophage activation in subjects with pre-therapy CD4>350.
All subjects had optimal viral suppression from weeks 24 through 48.
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Methods—Subjects (n=48) initiated cART with tenofovir/emtricitabine plus ritonavir-boosted
atazanavir. Data were collected at baseline and weeks 12, 24, and 48. Trends were compared to
uninfected controls.
Results—Significant increases over 48 weeks were noted in all CD4 populations including total,
naïve, central memory (CM), and effector memory RO (EM RO) and effector memory RA (EM
RA) while numbers of CM and EMRO CD8 cells declined significantly. By week 48, CD4 naïve
cells were similar to controls while CM CD4 cells remained significantly lower and EM RO and
EM RA subsets were significantly higher. CD38 and HLA DR expression, both individually and
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when co-expressed, decreased over 48 weeks of cART on CD8 cells but remained significantly
higher than controls at week 48. In contrast, markers of macrophage activation measured by
sCD14 and sCD163 in plasma did not change with cART and were significantly higher than
controls.
Conclusion—In youth initiating early cART, CD4 cell reconstitution is robust with decreases in
CD8 cells. However CD8 T cell and macrophage activation persists at higher levels than
uninfected controls.

Introduction

Author Manuscript

Infection with HIV-1 continues to impact youth in the US.1,2 While treatment with
antiretroviral therapy is now recommended for most infected individuals,3 data are limited
on the outcomes of antiretroviral treatment in infected youth who are unique for several
reasons. For example, compared to adults following continuous antiretroviral therapy
(cART), immune reconstitution in younger individuals shows higher proportions of naïve T
cells.4–8 The timing of sexual debut is often close to HIV-1 acquisition among behaviorally
infected adolescents indicating a relatively short duration of infection prior to initiating
therapy. In older adults longer duration of infection and lower nadir CD4+ T cell (CD4)
counts can diminish the depth and breadth of immune reconstitution.9–12 Younger age
predicts less inflammation-mediated morbidity and presents opportunities to reduce the
inflammatory consequences of HIV-1 infection such as cardiovascular disease.
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Even with optimal viral suppression and immune reconstitution, high levels of immune
activation following cART persist. While lack of adherence is a major cause of loss of viral
suppression among youth on cART,13–17 immune activation and chronic inflammation may
also contribute to viral breakthrough.18 Initiation of therapy before immune decline could
reduce immune activation to levels similar to a uninfected individuals. In this study we
examined changes in the distribution of naïve, memory, and effector memory T cell
populations and extent of T cell activation following 48 weeks of cART in a population of
youth with pre-therapy CD4 counts above 350 cells/mm3. We also determined if early cART
resulted in decline in macrophage activation biomarkers associated with inflammation
including soluble CD14 (sCD14) and soluble CD163 (sCD163).

Materials & Methods
Population

Author Manuscript

One hundred subjects from 23 clinical sites were enrolled between 2007 and 2010 into the
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) and the
International Maternal, Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT)
study ATN 061: Preservation and Expansion of T-cell Subsets Following HAART Deintensification to Atazanavir/ritonavir. Of one hundred subjects enrolled, 75 were
randomized to the early treatment arm with pre-entry CD4>350 cells/mm3 and begun on
cART with tenofovir/emtricitabine plus ritonavir-boosted atazanavir after resistance testing.
Forty-eight subjects achieved viral suppression, defined as HIV-1 RNA plasma viral load
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(VL) below 100 copies by week 24 and maintained through week 48, and are included in
these analyses.
Fifty-one HIV-1 uninfected participants (HIV-) based on single time-point laboratory
studies, similar to study cohort for age, gender, and African American ethnicity, were
enrolled from one site (University of South Florida) as controls. Inclusion criteria for control
subjects included no chronic illnesses or conditions, no infections or recent immunizations
prior to blood studies, and documented HIV-1 sero-negative status.
The study was approved by Institutional Review Boards at each participating site. A Data
Safety and Monitoring Board appointed by the Eunice Kennedy Shriver National Institute of
Child Health and Human Development reviewed the data from the study semiannually.

Author Manuscript

Procedures
Analyses for T- cell subsets, plasma VL, extended flow cytometry, and plasma soluble
factors were performed at entry and weeks 12, 24, and 48. Peripheral blood mononuclear
cells (PBMC) were obtained by Ficoll-Hypaque density centrifugation and cryopreserved at
−160°C.19 Plasma samples were stored at −80°C.
Flow cytometry analysis of T cells subsets
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Cryopreserved PBMCs were thawed, re-suspended in phosphate buffered saline containing
2% fetal bovine serum (PBS/2% FBS),20 divided into two tubes for incubation with antiCD197 (CCR7, BD Bioscience, San Jose, CA) at 37°C, 5 % CO2 for 30 minutes, followed
by incubation at 4°C for 30 minutes in a mixture of anti-CD3, anti-CD45RA, anti-HLA-DR,
anti-CD57 (all BD Bioscience, San Jose, CA), anti-CD38 (Life Technologies, Carlsbad, CA)
and either anti-CD4 or anti-CD8 (BD Bioscience, San Jose, CA). Cells were washed and resuspended in PBS/2% FBS.
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Markers of T cell differentiation/activation were analyzed with a multi-parameter LSR II
flow cytometer (BD Bioscience, San Jose, CA). Lymphocytes were defined based on the
forward scatter (FSC) and side scatter (SSC) from 100,000 events per sample. Lymphocyte
subpopulations were subsequently acquired by gating on CD3+CD4+ or CD3+CD8+ cells
identifying T helper and cytotoxic T cells, respectively. Naive CD4 and CD8 T cells were
enumerated by gating CCR7+ and CD45RA+ cells, T central memory (TCM) by gating
CD45RA− and CCR7+ T cells, T effector memory (EMRA) by gating CD45RA+ and
CCR7−, and T effector RO cells (EMRO) by gating CD45RA− and CCR7− (Figure 1). Each
subpopulation was individually analyzed for single expression and mean fluorescence
intensity (MFI) of CD28, CD38, or HLA DR (Figure 1),21 as well as dual expression of
CD38 and HLA DR. Data were acquired using BD FACSDiva acquisition software (BD
Bioscience, San Jose CA) and analyzed with FlowJo v9.4.11 (Treestar, Inc, San Carlos,
CA). Flow cytometry gates were established based on the cut-off determined by FMO
controls.22
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Commercially available ELISA kits were used to detect sCD14 (R & D Systems,
Minneapolis, MN), sCD27 (eBioscience, San Diego CA), and sCD163 (R & D Systems,
Minneapolis, MN) within previously frozen plasma stored at −80°C. sCD14 was measured
at a dilution factor 1:200 with a detection range of 250 – 8000 pg/ml; sCD27 at a dilution
factor of 1:50, detection range 0.31 – 20 U/ml; and sCD163 at a dilution factor of 1:20,
detection range of 1.6 – 100 ng/ml. The ELISA plates were read on Biotek® EL800
automated microplate reader (Winooski, VT) and results were analyzed using KCjunior™
microplate data analysis software, version 1.41.5 (Biotek®, Winooski, VT).
Statistical methods
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Expression of immunological markers and soluble factors was analyzed using slopes and
two-sample comparisons with healthy controls. Slopes of expression intensities over 48
weeks were estimated for each subject by linear regression and then analyzed by t-test to
assess whether mean slope equaled zero. Baseline and week 48 values for subjects were
compared with healthy controls using the Wilcoxon Rank-Sum test. Baseline and 48 week
comparisons were conducted with the overall data, as well as data stratified by baseline CD4
counts (≤500 cells/mm3 versus >500 cells/mm3). All p-values were two-sided with statistical
significance set at <0.05. Analyses were performed using SAS version 9.2.23

Results
Study Population

Author Manuscript

Forty-eight of the 75 subjects (64%) randomized to the treatment arm fully suppressed VL
to <100 copies/ml between 24 and 48 weeks with the combination of ritonavir-boosted
atazanavir, tenofovir, and emcitribine. Only two subjects had viral loads over 100 after week
24 (261 and 219 copies at week 36). Both subjects were below the level of detection with
repeat testing and were continued on study. Baseline demographics of subjects who
suppressed VL compared with the control group are shown in Table 1. The majority of
subjects were male (87.5%), identified as African American (67%), and had CD4 counts
above 500 cells/mm3 (58.33%). Substance use, including alcohol, tobacco, and marijuana,
was similar between subjects and controls, as reported previously.24 Other psychosocial
factors were not assessed as part of this study.
Expansion of CD4 and contraction of CD8 cells over 48 weeks on cART
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When compared to control youth, HIV-1 infected youth had significantly lower baseline
CD4 counts for total (p=0.0019), naïve (p=0.0055), and CM (p<0.0001) subsets (Figure 2A).
EM RA were higher (p=0.0019), but EM RO cells were not significantly different
(p=0.4573). Following cART, significant increases developed in all CD4 populations
including total (<0.0001), naïve (p=0.0029), CM (p=0.0001), and EM RO (p<0.0001) and
EM RA (p<0.0001) subsets (Figure 2A). When T cell subsets were compared after week 48
of cART, mean total CD4 counts were higher and not different from control individuals
(p=0.0543) (Figure 2A).
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Total CD8 T cells and CM, EM RA, and EM RO subsets were significantly higher between
subjects and controls (p<0.0001 for each), with no differences in CD8 naïve cells
(p=0.5275). (Figure 2B). Total CD8 T cells decreased after therapy initiation, although the
overall trend was not significant (p=0.0674). While no significant trends appeared for CD8
naïve or EM RA subpopulations, other populations, including CM (p<0.0001) and EM RO
(p=0.0006) subsets, decreased (Figure 2B).
Changes among CD4 and CD8 T cell subsets were analyzed based on subjects grouped by
baseline CD4 counts ≤500 or >500 cells/mm3. In each group, similar increases in total CD4
T cells, as well as CM, EM RO and EM RA CD4 populations occurred. Subjects with entry
CD4≤ 500 also showed significant increases in naïve cells (data not shown). For CD8 cells,
subjects in each CD4 strata demonstrated significant decreases in CM and EM RO
populations.
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Week 48 lymphocyte subsets compared to controls
At week 48, mean total CD4 T cell counts were not significantly different from control
individuals (p=0.0543) (Figure 2A). In subset analysis, cART resulted in normalizing of
CD4 naïve cells to levels similar to controls (p=0.1946), CM cells remained lower
(p<0.0001), while both EM RO and EM RA subsets were higher (p<0.0001 for both).
Total CD8 populations, as well as both EM RO and RA subsets were higher in subjects at
week 48 than in controls (p<0.0001 for each), whereas naïve and CM subsets were similar.
(Figure 2B) Although significant longitudinal decreases for some CD8 subsets (CM and EM
RO) occurred in subjects, elevated CD8 T cells persisted at week 48 driven by higher EM
RO and EM RA subsets.
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Decreased but persistent CD8 activation despite virologic suppression
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Immune activation within each CD8 T cell subset was assessed as percentage of cells
expressing CD28, CD38 or HLA DR at week 48 relative to earlier time points (Figure 3).
Control of VL resulted in significant longitudinal increases in the percentage of CD8 naïve,
CM, EM RA, and EM RO subsets expressing CD28 (p<0.0001 for each). (Figure 3A)
However, subjects at week 48 compared to controls had lower CD28 expression on naïve
(p=0.0072), CM (p<0.0001), and EM RO (p<0.0001) CD8 subsets, consistent with
persistent activation. Similar to down regulation of CD28, increased expression of CD38
and HLA DR reflects T cell activation. The percentage of cells expressing CD38 was higher
at baseline but declined on naïve, CM, EM RO, and EM RA CD8 subsets within subjects
(p<0.0001 for each time point post therapy). Expression of CD38 remained significantly
higher for all CD8 subsets (p<0.0001) and failed to normalize even after 48 weeks of cART
when compared to controls. Similarly, the percentage of cells expressing HLA DR
decreased at week 48 for all CD8 subsets within subjects (p<0.0001 for all). These decreases
led to percentages for naïve and EM RA CD8 subsets that were similar to controls, while
CM (p<0.0001) and EM RO (p<0.0001) subsets remained higher. Although co-expression of
CD38 and HLA-DR declined for each CD8 subpopulation (p<0.0001 for all, data not
shown), percentage co-expression remained elevated at week 48 for all subpopulations
(p<0.0001 for naïve, CM, and EM RO; p=0.0002 for EM RA) compared to controls.
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Assessment of activation markers on CD8 T cell subsets by MFI showed that by 48 weeks
CD28 increased, while CD38 and HLA DR decreased significantly on naïve, CM, EMRA,
and EMRO (p <0.001 for all) but failed to normalize compared to controls (p < 0.001)
(Supplemental Table S1).
Soluble factors of inflammation and activation
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The impact of cART on macrophage activation was evaluated by assessing changes over 48
weeks of treatment in plasma levels of sCD14 and sCD163, markers of innate activation,
along with sCD27, a soluble marker of lymphocyte activation. While sCD163 decreased,
sCD14 and sCD27 remained similar to baseline levels (Figure 4), and each factor persisted
at significantly higher levels compared to HIV-1 negative controls. The extent of elevation
in sCD14, sCD163, and sCD27 did not correlate with the levels of CD8 T cell activation
based on expression of HLADR or CD38 on naïve, CM, EMRA, or EMRO subsets either at
entry or after 48 weeks (data not shown).

Discussion

Author Manuscript

Since the time that ATN 061 was initiated in 2008 , treatment guidelines have shifted to
recommend cART at early stages of HIV infection as standard of care.3 As HIV incidence
continues to be high in youth, especially ethnic minority young men who have sex with men
(MSM), understanding the risks and benefits of early therapy in this population is
essential.1,2 Treatment of young adults in early stage of disease, where there is a shorter
interval from infection to treatment and higher capacity for immune reconstitution could
result in preservation of T cell homeostasis,25,26 and lower the risk HIV inflammatory
complications such as cardiovascular disease.4–12 In our study of youth who initiated
treatment when CD4 counts were above 350 cells/mm3 or even greater than 500 cells/mm3,
T cell reconstitution by 48 weeks was robust, T cell activation was diminished, while
macrophage activation persisted. Thus, despite early treatment and successful viral control
in this younger cohort, T cell activation and inflammation persisted similar to chronic
infection in older adults.

Author Manuscript

The subjects in ATN 061 were therapy naïve, initiated treatment prior to immunologic
deterioration, and were treated with the same antiretroviral regimen with close monitoring to
assure documentation of viral suppression. At the time ATN 061 was implemented,
atazanavir was a recommended first line component of cART. Subsequent availability of
darunavir might have advantages for treatment of HIV-infected youth,27–29 although
darunavir or atazanavir are similarly effective with similar metabolic profiles compared to
efavirenz as part of cART,30,31 The HIV-uninfected controls and infected subjects in this
study were similar for gender, age, and race, but co-existing conditions such as infection by
herpes viruses, mycobacterium, or other sexually transmitted diseases that may be prevalent
among the infected youth but were not captured as confounding variables, might contribute
to immune activation. Although measures of immune activation and inflammation are not
part of standard monitoring in the clinical setting, determination of levels in the research
setting provides critical insights into the impact of therapy. In our study, viral suppression
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was maintained even with persistent immune activation. Conversely, immune activation was
independent of viral breakthrough.
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While viral replication differentially impacts T cell immune activation, primarily within
CD8 CM and EM populations,23,32–34 control of viral replication should reestablish
distribution of populations that are poised to return to normal levels.35 The capacity to
rapidly express or down-regulate activation markers on CM and EM CD8 cell subsets
suggests that assessment of discrete T cell populations has utility in monitoring immune
activation in HIV-infected patients on cART as the extent of CD38 expression within CD8
subsets and levels of cell-associated virus predict disease progression in untreated HIVinfected adults.36 A surprising result among the youth with sustained viral suppression after
48 weeks of cART was continued elevation in CD38 on CM and EM CD8 T cells and the
failure to normalize CD28 when compared to uninfected controls. Longer duration of
optimal viral suppression may be needed before these signs of T cell activation decline in
younger individuals.
In HIV-infected older adults who initiate therapy after CD4 counts decline to less than 350
cells/mm3, the extent to which CD4 cells normalize is much lower than in adolescents who
initiate ART early in infection.4,5,37,38 Early therapy and persistence of thymic function is
associated with improved immunologic outcomes in adults, children and adolescents treated
with antiretroviral therapy.4–12,25,26 While gains in naïve CD4 cell T cells occur in most
youth in our study, increases are most apparent among subjects with lower baseline CD4
counts at baseline; by 48 weeks of cART naïve CD4 T cells were similar to uninfected youth
reflective of restored T cell homeostasis.
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HIV-1 infection primes macrophages for activation and accentuates LPS-induced
macrophage activation through TLR-4, as measured by the levels of sCD14 and sCD163 in
the plasma.39–43 There was no correlation between changes in macrophage activation and
the extent of T cell activation when expression of CD38 and HLADR expression was
correlated to levels of sCD14 and sCD163. These results further illustrate independent
mechanisms of innate and adaptive immune activation. Elevations in sCD14 and sCD163
persisted in spite of cART and were significantly higher than controls. Macrophage
activation contributes to the long-term inflammatory complications of HIV-infection and
appears to be independent of viral replication.44–46 Persistent macrophage mediated
inflammation among youth who are asymptomatic with normal CD4 cell counts emphasizes
the need for early interventions to reduce the long term inflammatory consequences of HIV
infection.

Author Manuscript

sCD27 is a member of the tumor necrosis family released into the plasma following
lymphocyte activation47 and like activation markers measure using flow cytometry,
persistence of sCD27 in the plasma indicates ongoing immune activation.47–49 Elevated
level of sCD27 when compared to controls further supports the observation that lymphocyte
activation is not completely reversed by effective cART and provides another biomarker of
lymphocyte activation that is not dependent on extended flow cytometry. Previous studies in
adults and children show continued gains in CD4 cells and declines in inflammatory markers
can be achieved with long term viral suppression but years of treatment are required.50–52

J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 01.

Rudy et al.

Page 8

Author Manuscript

Immune activation during early infection is independently associated with CD4 cell loss in
untreated individuals.53 Data in older adults indicate that the impact of CD8 cell activation
on AIDS or non-AIDS events is confounded by age with those subjects over 50 more at risk
for co-morbid events.54 CD38 expression on CD8 cells is associated with disease
progression in adolescents as measured by CDC disease classification.34 The long term
follow-up of the subjects enrolled in ATN 061 will prove whether expression of CD38 on
CM and EM CD8 cells can predict viral failure while receiving cART and better understand
the impact of initial immune activation and inflammation on treatment outcomes in young
adults.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. T cell subsets and expression of activation markers in PBMC

Flow cytometry of T cells gated on CD3+CD4+ T cells (panels A and B) or CD3+CD8+ T
cells (panels C and D) from representative uninfected (HIV−) and HIV-infected (HIV+)
subjects. Panels A and C show density contour plots of CCR7 and CD45RA expression in
CD4+ T cells (A & B) and CD8+ T cells (C & D). T cell subsets are defined as Naïve (CD3+
CD4/8+ CD45RA+ CCR7+); TCM (CD3+ CD4/8+ CD45RA− CCR7+); TEMRO (CD3+
CD4/8+ CD45RA−CCR7−); and TEMRA (CD3+ CD4/8+ CD45RA+ CCR7−). Percentage of
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cells based on FMO controls are shown for each quadrant. Activation markers CD28, CD38,
and HLA DR are shown (B & D) as overlaid histogram plots for each subset.
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Figure 2. Trends in mean CD8+ and CD4+ T cells following antiretroviral therapy

The y axis shows change in total cells/mm3 for CD4+ T-cell subsets (panel A), change in
CD4+ T-cell in HIV+ subjects with baseline CD4+ T-cells >500 cells/mm3 (panel B), and
with baseline CD4+ T-cells ≤ 500 cells/mm3 (panel C). Change in CD8+ T-cell subsets
(panel D), CD8+ T-cell subsets in HIV+ subjects with baseline CD4+ T-cells > 500
cells/mm3 (panel E), and with baseline CD4+ T-cells ≤ 500 cells/mm3 (panel F) are also
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shown. Bars represent baseline ( ), week 12 ( ), week 24 ( ), week 48 ( ), and HIV −
controls ( ) and are shown for each subset. Significant changes over 48 weeks are shown
with arrows. Changes from entry to 48 weeks among HIV+ subjects are represented with (*)
(p<0.05, Wilcoxon Rank-Sum test). Significant differences between HIV+ subjects at
baseline to HIV− controls and HIV+ subjects at 48 weeks to HIV− controls are shown with
(†) and (‡), respectively (p<0.05, Wilcoxon Rank-Sum test). Error bar indicates 1 standard
deviation.
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Figure 3. Trends in mean expression of T cell activation markers on CD8+ T cells

Change in percent expression of CD28 (panel A), CD38 (panel B), and HLA-DR (panel C)
are shown for each subpopulation. Bars represent baseline ( ), week 12 ( ), week 24 ( ),
week 48 ( ), and HIV− controls ( ). Significant changes over 48 weeks are shown with
arrows. Changes from entry to 48 weeks among HIV+ subjects are represented with (*)
(p<0.05, Wilcoxon Rank-Sum test). Significant differences between HIV+ subjects at
baseline to HIV− controls and HIV+ subjects at 48 weeks to HIV− controls are shown with
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(†) and (‡), respectively (p<0.05, Wilcoxon Rank-Sum test). Error bar indicates 1 standard
deviation.
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Figure 4. Trends in mean levels of plasma biomarkers of macrophage and lymphocyte activation

Panels show levels of sCD14 levels (ng/ml) (panel A), sCD27 levels (U/ml) (panel B) and
sCD163 levels (ng/ml) (panel C). The horizontal red line indicates mean values. Significant
changes between baseline and 48 weeks in HIV+ subjects are represented with * (p<0.05,
Wilcoxon Rank-Sum test). Significant differences between HIV+ subjects and HIV−
controls are shown with † (p<0.05, Wilcoxon Rank-Sum test).
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Baseline and Demographic Data

Variable

HIV infected
(N=48)

HIV
uninfected
(N=52)

p-value

20.90 (1.55)

21.62 (2.11)

0.0533

18 – 24

18 – 25

Age at Entry (Years) - Continuous
  Mean (SD)
  Range
Age at Entry (Years) - Categorical

0.2160

  18 – 20

21 (43.75)

16 (30.77)

  Over 21

27 (56.75)

36 (69.23)

Gender

0.1317

Author Manuscript

  Male

42 (87.50)

39 (75.00)

  Female

6 (12.50)

13 (25.00)

  African American

32 (66.67)

35 (67.31)

  Other

16 (33.33)

17 (32.69)

Race

1.0000

Baseline CD4+ Count
  < 350

0.0028
0 (0)

4 (7.69)

  350 – 500

20 (41.67)

8 (15.38)

  > 500

28 (58.33)

40 (76.92)

Baseline CD4+ Percent

<0.0001

Author Manuscript

  < 15%

2 (4.17)

1 (1.92)

  15-25%

19 (39.58))

1 (1.92)

  > 25%

27 (56.25)

50 (96.15)

Baseline CD4+ Count
  Mean (SD)

553 (158)

730 (284)

  Range

355 – 1107

192 – 1416

  Mean (SD)

27.07 (8.60)

41.94 (9.70)

  Range

0.19 – 55.00

12.00 – 60.00

  Mean (SD)

20916 (21574)

NA

  Range

1152 – 88900

0.0002

Baseline CD4+ Percent (%)
<0.0001

Baseline viral load

CD4 count, CD4 percentage and Viral Load from the Pre-Entry visits were used as Baseline. P-values were calculated using Fishers exact test for
categorical variables and t-test for continuous variables.
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